Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's noodle row and spill-over effects for pharma

This article was originally published in Scrip

Executive Summary

Nestle's run-in with Indian regulators over its popular noodle brand, Maggi, being "unsafe" and hazardous" for human consumption may just have put the spotlight on the fast-growing nutraceuticals segment quite like the heightened focus on site compliance in the aftermath of "Ranbaxygate" some years ago.

You may also be interested in...



Star Power: How Celebrity Endorsement Is Shaping Pharma In India

Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?

Star Power: How Celebrity Endorsement Is Shaping In India Pharma

Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?

Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'

Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative”. The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel